Inactief instrument

Andere talen Arsanis Inc Nasdaq

Aandelen

US0428731097

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference	13/05
Sector Update: Health Care Stocks Higher Late Afternoon	09/05
X4 Pharmaceuticals Receives $125 Million Additional Capital; Shares Rise	09/05
X4 Pharmaceuticals, Inc. Draws an Additional Tranche of $20 Million Under Its Existing Loan Facility with Hercules Capital, Inc	09/05
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility	09/05
X4 Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
X4 Pharmaceuticals: Q1 Earnings Snapshot	07/05
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates	07/05
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/05
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024	30/04
Pantherx® Rare Partner with X4 Pharmaceuticals Inc. for the Distribution of Xolremdi? (Mavorixafor), the First FDApproved Therapy Indicated for Use in Patients with Whim Syndrome	29/04
X4 Pharmaceuticals' Xolremdi Approved by FDA For WHIM Syndrome	29/04
X4 Pharmaceuticals Gets FDA Approval for Xolremdi Capsules	29/04
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome	29/04
X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome	29/04
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	03/04
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/04
X4 Pharmaceuticals : Regulation FD Disclosure - Form 8-K	01/04
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences	01/04
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	21/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Arsanis Inc Nasdaq

Aandelen

US0428731097

Andere talen

Filters